Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

about

Molecular Mechanisms Directing Migration and Retention of Natural Killer Cells in Human Tissues

P2860

Q58572875-CC3E9502-B8CB-4CE4-94A7-E94149965A97

P2860

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

Item

http://www.wikidata.org/entity/Q42266048

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Reversibility of the effects o ...... cell dynamics in MS patients.

@en

Reversibility of the effects o ...... cell dynamics in MS patients.

@nl

type

Item

label

Reversibility of the effects o ...... cell dynamics in MS patients.

@en

Reversibility of the effects o ...... cell dynamics in MS patients.

@nl

prefLabel

Reversibility of the effects o ...... cell dynamics in MS patients.

@en

Reversibility of the effects o ...... cell dynamics in MS patients.

@nl

P1476

Reversibility of the effects o ...... cell dynamics in MS patients.

@en

P2093

Alison Adams

http://www.w3.org/2001/XMLSchema#string

Bruce A C Cree

http://www.w3.org/2001/XMLSchema#string

Daniel Mikol

http://www.w3.org/2001/XMLSchema#string

Diogo Amarante

http://www.w3.org/2001/XMLSchema#string

Douglas Jeffery

http://www.w3.org/2001/XMLSchema#string

Geoffrey Kuesters

http://www.w3.org/2001/XMLSchema#string

Ivan Nestorov

http://www.w3.org/2001/XMLSchema#string

Jerome De Sèze

http://www.w3.org/2001/XMLSchema#string

Karleyton Evans

http://www.w3.org/2001/XMLSchema#string

Kumar Kandadi Muralidharan

http://www.w3.org/2001/XMLSchema#string

P2860

Natalizumab exerts direct signaling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis

Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

Extended interval dosing of natalizumab in multiple sclerosis.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.

Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.

Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.

Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

P304

1584-1593

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000004485

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hans-Peter Hartung

Bianca Weinstock-Guttman

Ludwig Kappos

P577

2017-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28916537

http://www.w3.org/2001/XMLSchema#string

P932

5634662

http://www.w3.org/2001/XMLSchema#string

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

about

P2860

P2860

Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932